ecancermedicalscience

Short Communication

Current perspectives on skeletal health and cancer progression across the disease continuum in breast cancer—the role of bisphosphonates

23 Aug 2012
R Aft

Pre-clinical and clinical evidence suggest that bisphosphonates inhibit both bone resorption and cancer progression. New and updated analyses from several large, controlled studies in pre- and post-menopausal women with early stage breast cancer (BC) suggest that addition of bisphosphonates improves cancer-related outcomes, particularly in patients with a ‘low-estrogen environment’. Further, preliminary clinical data suggest that bisphosphonate therapy may reduce circulating tumour cell numbers (a negative prognostic indicator of disease-free and overall survival) in patients with advanced/metastatic disease. These new findings warrant reconsideration of the therapeutic role of bisphosphonates in BC.

Related Articles

Tinashe Adrian Mazhindu, Ntokozo Ndlovu, Margaret Borok, Vincent Aketch Nyangwara, Pageneck Chikondowa, Marie Hidjo Madeleine, Collen Masimirembwa, Onesai Chihaka, Edith Matsikidze, Charley Jang, Kevin Grimes
Carl Arenos, Steven Lim, Andreu Lominoque, Isabela Reveldez, Angeli Sison-Dimaano, Nehar Pagandaman, Vincent Tatoy, Timothy Uy, Michael San Juan
Samuel Santiago Parra Giraldo, Rut Amparo Vergara López, Haydee De La Hoz-Herazo, Enrique Carlos Ruiz Pla, Brayan Bayona-Pacheco, Juan Jose Espitia De La Hoz
Seema Rajesh Rao, Mithili Narayan Sherigar, Michelle Normen, Udita Joshi